Scleroderma Archives - Rheumatology Advisor

Pulmonary Function Tests May Underdiagnose Interstitial Lung Disease in Juvenile Systemic Sclerosis

By

Emily Pond

November 20, 2020

Study authors determined the performance of pulmonary screening vs HRCT in detecting interstitial lung disease in juvenile SSc.

Scleroderma

Gastrointestinal Transit Abnormalities Associated With Severe GI Symptoms in Scleroderma

By

Amit Akirov, MD

November 19, 2020

Researchers evaluated the contribution of abnormal GI transit to systemic sclerosis Medsger GI severity scores and/or UCLA GIT 2.0 symptoms.

ACR Convergence 2020

Assessing the Long-Term Safety and Efficacy of Tocilizumab in Systemic Sclerosis

By

Rheumatology Advisor Contributing Writer

November 8, 2020

The long-term safety and efficacy of tocilizumab in patients with systemic sclerosis were assessed in an open-label study.

ACR Convergence 2020

Higher Neutrophil Count Linked to Mortality in Systemic Sclerosis-Related Interstitial Lung Disease

By

Britt Gambino

November 6, 2020

A higher neutrophil count predicted worse disease course and higher long-term mortality in patients with systemic sclerosis-related interstitial lung disease.

Scleroderma

Iloprost Can Reverse Vascular Dysfunction in Scleroderma

By

Emily Pond

October 27, 2020

Researchers evaluated the cellular mechanism of iloprost in reversing vascular dysfunction in scleroderma.

Pediatric Rheumatology

Elastography Ultrasound Feasible in Assessing Disease Activity in Pediatric-Onset Localized Scleroderma

By

Emily Pond

October 22, 2020

Researchers determined the feasibility of elastography ultrasound in the assessment of pediatric-onset localized scleroderma.

Scleroderma

Evaluating Novel Classifications for Systemic Sclerosis

By

Emily Pond

October 8, 2020

Recent studies have evaluated new approaches to understand the heterogeneity of systemic sclerosis by optimizing disease classification.

Scleroderma

Gene Expression in Patients With Severe Scleroderma May Predict Stem Cell Transplant Response

By

Amit Akirov, MD

September 29, 2020

Researchers determined whether machine learning could predict stem cell transplant response in severe scleroderma.

Ischemic stroke is the most common severe neurologic complication of APS. Among 1000 people with APS participating in the Euro-Phospholipid Project, 20% presented with stroke and 11% presented with transient ischemic stroke.2,5 About 13% of patients with stroke are aPL-positive,2 and they are more likely to be younger or female compared with aPL-negative patients.3 More than 20% of strokes in patients <45 years may be related to APS.3 In APS, stroke occurs when a clot forms in an arterial vessel of the brain or when clot or plaque debris travels from another site (usually the heart) to a blood vessel in the brain.2,3 Less common cerebrovascular diseases seen in patients with APS that may increase stroke risk are cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome, acute ischemic encephalopathy (a rare feature of SLE), and Sneddon syndrome.3 To reduce stroke risk, clinicians may want to discuss modifiable risk factors for vascular disease, such as smoking and obesity, with those who are positive for aPL.3 Image Credit: Zephyr/Science Source

Scleroderma

Similar Outcomes for Ischemic Stroke Hospitalizations With and Without Systemic Sclerosis

By

Alyssa Capel

September 29, 2020

Researchers compared the hospitalization outcomes of patients with ischemic stroke with and without a secondary diagnosis of systemic sclerosis.

Scleroderma

Adverse Event Profile of Nintedanib in SSc-ILD Consistent With its Safety, Tolerability Profile in Idiopathic Pulmonary Fibrosis

By

Emily Pond

September 29, 2020

Researchers characterized the safety and tolerability of nintedanib and the dose adjustments for adverse events in patients with systemic sclerosis-associated interstitial lung disease.